Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 25.25p 24.50p 26.00p 25.25p 25.25p 25.25p 43,293.00 07:50:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 48.5 -12.1 -2.3 - 149.84

Allergy Therapeutics Share Discussion Threads

Showing 3326 to 3350 of 3350 messages
Chat Pages: 134  133  132  131  130  129  128  127  126  125  124  123  Older
DateSubjectAuthorDiscuss
15/2/2017
17:13
If they go alone they will likely need more cash but given the longer-term potential that doesn't concern me.
audigger
15/2/2017
15:51
Well Gold digger, if they do make their interims on March 29th, this should pop it's cork if my hunch is right. It has been a long time coming. The failure last year was costly from many perspectives. But they are a solid business with an ever widening portfolio. My question is are they big enough to develop all of these products. When I read headlines saying xyz from AGY is 'TALKING UP' prospects of etc etc, it make me think, cash call must be in the wind. impo/dyor Happy to sit tight now.
jimmyloser
15/2/2017
08:45
There's a new interview on Directors talk with Dr Gary Waanders, Director of Healthcare Research at Zeus Capital who talks about Acrovac and Allegy Therapeutics in general: http://www.directorstalk.net/interview-allergy-therapeutics-plc-acarovac-sales-top-500m-zeus-capital/
timbo003
15/2/2017
07:33
Allergy Therapeutics CEO Murray Skinner speaks to Proactive about their phase I clinical study of Acarovac MPL receiving official sign-off in Spain. A total of 32 patients will receive Acarovac, which will be administered at two different doses. The trial is expected to take 12 months from start to finish. http://www.proactiveinvestors.co.uk/companies/stocktube/6911/allergy-therapeutics-murray-skinner-talks-up-huge-market-opportunities-for-dust-mite-treatment-6911.html
timbo003
14/2/2017
07:29
Another small step towards the end-game. I still think we'll drift back in the short-term but am happy to be proved wrong. These are still very cheap given the potential so I plan to add as cash allows throughout 2017.
audigger
14/2/2017
07:05
And more good news, March 29th could see this go through the next threshold (30p) if it hasn't done so before. All of this takes time and more importantly......cash!
jimmyloser
13/2/2017
15:19
AuDigger, I actually don't see this drifting too much. There is so much good stuff around however the price is being weighed down by last years failure in the USA. March 29th could unclip that chain when we get some meat on the bones as to where we are in relation to the new trials. There is little doubt that they are very upbeat with what they have been saying and allowing to be said of late. Patience is needed in stocks like these. and no more set backs! impo/dyor
jimmyloser
10/2/2017
16:20
Looks like we'll drift for a while as is the way of things. I'm hoping its back at 18p come April so I can top-up with the new tax year's ISA allowance!
audigger
03/2/2017
11:21
Is it starting to pull back or are we poised for the attack on 30p?
audigger
01/2/2017
19:52
Upside still to be seen according to analyst. Allergy Therapeutics (LON:AGY) will take its Polyvac vaccine for peanut allergy into a phase I clinical trial after it delivered positive pre-clinical results. The findings showed a single dose of the company's unique adjuvant when combined with recombinant peanut allergen successfully protected against the serious allergic reaction anaphylaxis. The company is developing Polyvac as a short course of injections that is safer and more effective than the current treatments. “Hundreds of patients die each year in the United States as a result of food allergies (mainly peanut) and we are committed to saving these lives,” said Allergy Therapeutics chief executive Manuel Llobet. “This peanut vaccine programme complements our current range of marketed ultra-short course vaccines in terms of safety, efficacy and improved patient convenience." The shares rose 6% in afternoon trade to 27.5p. However the company’s broker, finnCap, thinks they have further to go. Analyst Mark Brewer points out Allergy trades on an enterprise value/sales multiple of just two-times when its peers are on 3.2-times. He reckons the shares are worth 43p each with “substantial further upside” as its hay fever drug Pollinex Quattro progresses through the development phases. “We currently attribute no value to Polyvac Peanut and will re-assess as it moves into human studies,” said Brewer. ---adds broker comment, share price---
jimmyloser
01/2/2017
15:34
Medical director Dr Matthias Kramer talks to Proactiveinvestors. hTTp://tinyurl.com/j5v75z2
shauney2
01/2/2017
11:49
I wouldn't get too excited. New products such as this take ages to get to the market and of course lot's of cash. Steady and solid progress is being seen. For me, it is March 29th when I look forward to meat on the bones. impo/dyor
jimmyloser
01/2/2017
11:04
Yep. Wait until this gets mentioned in the press
guyswonga74
01/2/2017
08:10
I have been waiting a long time for this to rocket, must be over 10 years since I bought. Have help throughout the pain of FDA issues. Hope this carries on up as my investment is now working. Good pipeline of products going forward
richsawko
01/2/2017
07:35
I know we have heard about AGY's innovative adjuvants before, but is this the first time we have heard the term "Virus like particles" (VLPs) when referring to one of their new adjuvants? (jimmyloser: post #3200, very good!)
timbo003
01/2/2017
07:24
Hence all the publicity and news on Bencard a few weeks ago!! and the going public in the press. All these things are stage managed and whoever is doing it, is doing a great job!! Watch the press and world media to-day! dyor/impo.
jimmyloser
01/2/2017
07:20
Now we know the what stirred those pigeons. Good news. Suddenly a whole new opportunity looks like a reality
audigger
01/2/2017
07:09
And to think you have been able to buy these shares for peanuts!! Incredible piece of news to wake me from my slumbers this morning. Well Done all at AGY! I said yesterday that something had stirred this!
jimmyloser
31/1/2017
13:54
Something has stirred the pigeons here in the last few minutes....mm
jimmyloser
30/1/2017
15:05
Good article....well balanced. Was away last week so hadn't seen that the share price made another move north. Lets hope it can now hold at this level before going beyond 30p.
audigger
30/1/2017
07:10
The Telegraph: Not to be sneezed at: profit versus peril in race for allergy vaccines. http://google.com/newsstand/s/CBIw08ORkzQ
dds14
23/1/2017
09:29
New telephone interview on Directors Talk: INTERVIEW: Zeus Capital Upgrade forecast for Allergy Therapeutics Plc NewsTeam, 23 Jan 08:11 AM Allergy Therapeutics Plc (LON:AGY) is the topic of conversation when DirectorsTalk caught up with Dr Gary Waanders the Director of Healthcare Research at Zeus Capital. Gary explains whats driven growth in the 6 months to Dec 31st, affects on the full year and what other things should we be focusing on for Allergy Therapeutics.......(cont) http://bit.ly/2khIXYV
timbo003
20/1/2017
08:04
Wonder why they didn't just say it plainly in the trading update instead of paying Hardman to do it.
paleje
20/1/2017
07:59
I am sure that you are not on your own AU. Watch this space.
jimmyloser
20/1/2017
07:38
All lining up for the share price to make an assault on 30p.....But when this will happen who knows! I'd be happy with a pull back in the short term so I can top up.
audigger
Chat Pages: 134  133  132  131  130  129  128  127  126  125  124  123  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V: D:20170223 11:33:46